Tying the authorization is important because this mechanism, the WTO decision that CAMR is based on and that Canada adopted, was carefully defined and limited.
It was not intended to be a broad-based infringement of existing intellectual property rights, but in the circumstances of there being a particular need identified by a particular country for a particular quantity of drugs, there would be a mechanism consistent with international rules allowing Canada to send drugs.
So untying the system from this particular need being identified in terms of quantity and by country is different from what was envisaged by countries.